31 completed, 12 terminated, 6 withdrawn, 5 active not recruiting. 19 Phase 1, 19 Phase 2, 14 Not applicable, 6 Early Phase 1, 1 Phase 3.
Follow alovudine: new trials by email Literature Review of alovudine trials Research Report on alovudine
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| Chemical-Shift-Encoded MRI for Active Bone Marrow Dosimetry in Radiopharmaceutical Therapy 3'-Deoxy-3'-[18F]-fluorothymidine, Chemical-shift-encoded MRI - Metastatic Castration-resistant Prostate Cancer | Early Phase 1 | Recruiting | University of Wisconsin, Madison | 15 | 2026-10-16 | 2026-10-23 |
| Androgen Deprivation, With or Without pTVG-AR, and With or Without T-Cell Checkpoint Blockade, in Patients With Newly Diagnosed, High-Risk Prostate Cancer Degarelix, pTVG-AR, Nivolumab - Prostate Cancer | Phase 1 / Phase 2 | Active not recruiting | University of Wisconsin, Madison | 57 | 2021-12-16 | 2026-09-30 |
| Testing Treatment With Encorafenib and Binimetinib Before Surgery for Melanoma With Lymph Node Involvement Binimetinib, Conventional Surgery, Encorafenib - Melanoma of Unknown Primary, Metastatic Malignant Neoplasm in Lymph Node | Phase 2 | Terminated | ECOG-ACRIN Cancer Research Group | 3 | 2021-09-22 | 2026-10-06 |
| SARC037: A Phase I/II Study to Evaluate the Safety of Trabectedin in Combination With Irinotecan in Ewing Sarcoma Patients Trabectedin 1 MG [Yondelis], Irinotecan, tumor biopsy - Ewing Sarcoma | Phase 1 / Phase 2 | Completed | Sarcoma Alliance for Research through Collaboration | 37 | 2021-01-05 | 2025-12-17 |
| Fluorothymidine F-18 PET in Diagnosing Patients With Intermediate or High Grade Soft Tissue Sarcoma Fluorothymidine F-18, Laboratory Biomarker Analysis, Positron Emission Tomography - Stage II Adult Soft Tissue Sarcoma, Stage IIA Adult Soft Tissue Sarcoma | Early Phase 1 | Withdrawn | OHSU Knight Cancer Institute | 2020-06-01 | 2020-06-09 | |
| [18F]Fluciclovine and [18F]FLT PET/CT Assessment of Primary High-Grade Brain Tumors [18F]FLT, [18F]Fluciclovine - Brain Tumor | Phase 1 / Phase 2 | Terminated | University of Utah | 10 | 2018-09-24 | 2024-12-27 |
| Multi-modality Imaging and Collection of Biospecimen Samples in Understanding Bone Marrow Changes in Patients With Acute Myeloid Leukemia Undergoing TBI and Chemotherapy Biospecimen Collection, Dual-Energy Computed Tomography, Fluorothymidine F-18 - Acute Lymphoblastic Leukemia, Acute Myeloid Leukemia | Early Phase 1 | Active not recruiting | City of Hope Medical Center | 82 | 2018-02-15 | 2026-06-08 |
| Role of Interim 18F-FLT PET/CT for Outcome Prediction in Pancreatic Adenocarcinoma 3'-deoxy-3'-[F-18] fluorothymidine: [F-18]FLT, Computed Tomography, Positron Emission Tomography - Pancreatic Adenocarcinoma | Phase 2 | Completed | University of Texas Southwestern Medical Center | 6 | 2017-12-11 | 2022-11-08 |
| Pilot Study of Biomarkers of Response to Immune Checkpoint Blockade in Metastatic Melanoma F-FDG PET/CT - Melanoma | Completed | University of Wisconsin, Madison | 5 | 2017-11-02 | 2026-01-28 | |
| 18-FLT PET/MR Imaging to Predict Graft Failure and GVHD in Bone Marrow Transplant Patients Fluorothymidine (FLT) - Graft Vs Host Disease | Early Phase 1 | Terminated | UNC Lineberger Comprehensive Cancer Center | 10 | 2017-01-01 | 2024-12-10 |
| 18F-FLT PET Imaging in Patients With Advanced Melanoma fludeoxyglucose F 18, Positron emission tomography-computed tomography, 18F-fluorothymidine - Melanoma | Phase 1 | Terminated | Washington University School of Medicine | 4 | 2016-10-10 | 2019-07-17 |
| FLT PET/CT in Measuring Response in Patients With Previously Untreated Acute Myeloid Leukemia Biospecimen Collection, Bone Marrow Aspiration, Bone Marrow Biopsy - Acute Myeloid Leukemia | Phase 2 | Active not recruiting | National Cancer Institute (NCI) | 87 | 2016-04-20 | 2026-09-23 |
| [18F]FLT PET/CT in Rb+ Metastatic Breast Cancer [18F]FLT, PET/CT, ribociclib - Breast Neoplasm, Metastatic Breast Cancer | Phase 1 | Active not recruiting | University of Pennsylvania | 20 | 2015-11-01 | 2026-10-07 |
| Fluoro-L-Thymidine Positron Emission Tomography (FLT PET) vs. Adv. Magnetic Resonance (MR) Techniques in Recurrent Glioma PET Scan, 3'-Deoxy-3'-18f-Fluorothymidine - Brain Tumor | Not applicable | Withdrawn | M.D. Anderson Cancer Center | 2015-06-01 | 2016-02-26 | |
| VEGFR/PDGFR Dual Kinase Inhibitor X-82 and Docetaxel in Treating Patients With Solid Tumors VEGFR/PDGFR dual kinase inhibitor X-82, docetaxel, fluorine F 18 fluorothymidine - Unspecified Adult Solid Tumor, Protocol Specific | Phase 1 | Completed | University of Wisconsin, Madison | 14 | 2014-09-01 | 2019-11-18 |
| Serial FLT PET Imaging in Cancer Patients for Monitoring of Response to Therapy [18F] FLT, PET/CT scans - Histologically-confirmed Malignancies | Not applicable | Withdrawn | Memorial Sloan Kettering Cancer Center | 2014-05-01 | 2019-09-17 | |
| FLT-PET/MRI for Early Response Monitoring to Novel Cancer Therapeutic Agents fluorine F 18 fluorothymidine, positron emission tomography, magnetic resonance imaging - Unspecified Adult Solid Tumor, Protocol Specific | Completed | Case Comprehensive Cancer Center | 10 | 2013-10-22 | 2020-09-18 | |
| 18F-FLT Positron Emission Tomography and Diffusion-Weighted Magnetic Resonance Imaging in Planning Surgery and Radiation Therapy and Measuring Response in Patients With Newly Diagnosed Ewing Sarcoma fluorine F 18 fluorothymidine, fludeoxyglucose F 18, positron emission tomography - Adult Supratentorial Primitive Neuroectodermal Tumor (PNET), Ewing Sarcoma of Bone | Early Phase 1 | Completed | Mayo Clinic | 1 | 2013-03-01 | 2017-11-20 |
| 18F-FLT PET/CT in Measuring Cell Proliferation in Patients With Brain Tumors Computed Tomography, Fluorothymidine F-18, Positron Emission Tomography - Metastatic Malignant Neoplasm in the Brain, Primary Brain Neoplasm | Not applicable | Completed | University of Washington | 9 | 2012-11-01 | 2020-01-13 |
| [F-18] Fluorothymidine PET/CT Imaging for Pelvic Cancers fluorothymidine F 18 - Uterine Cervical Neoplasms, Endometrial Neoplasms | Phase 2 | Completed | John M. Buatti | 36 | 2012-10-01 | 2019-03-26 |
Showing 20 of 56. Sign in to see all of them.
Brain Neoplasms (10) · Breast Neoplasms (8) · Carcinoma, Non-Small-Cell Lung (5) · Head and Neck Neoplasms (4) · Neoplasms (4) · Central Nervous System Neoplasms (3) · HIV Infections (3) · Leukemia, Myeloid, Acute (3) · Lung Neoplasms (3) · Melanoma (3) · Astrocytoma (2) · Carcinoma, Renal Cell (2) · Ependymoma (2) · Glioblastoma (2) · Glioma (2)
National Cancer Institute (NCI) (10) · University of Wisconsin, Madison (4) · Lederle Laboratories (3) · Mayo Clinic (3) · University of Utah (3) · University of Washington (3) · Dana-Farber Cancer Institute (2) · M.D. Anderson Cancer Center (2) · Siemens Molecular Imaging (2) · AHS Cancer Control Alberta (1) · Abramson Cancer Center at Penn Medicine (1) · Angiochem Inc (1) · Barbara Ann Karmanos Cancer Institute (1) · Case Comprehensive Cancer Center (1) · City of Hope Medical Center (1)
United States (47) · Canada (1) · France (1) · Netherlands (1) · Taiwan (1)
Glenn Liu (2) · Jeffrey Yap, PhD (2) · A. Bapsi Chakravarthy, MD (1) · Alexander M. Spence, MD (1) · Arthur Y Hung, MD (1) · Bernard Fine, M.D. (1) · Betty Lawrence (1) · Charles M Intenzo, MD (1) · Christopher G Kanakry, M.D. (1) · Daniel Kadrmas, PhD (1) · Daniella Pinho, MD (1) · David Mankoff, MD, PhD (1) · Douglas McNeel, MD (1) · Ebrahim S Delpassand, MD (1) · Eric Rohren, MD, PHD (1)
PMID 18543042, PMID 25207403, PMID 26359256, PMID 27319286, PMID 28371832, PMID 28570723, PMID 29248669, PMID 39670843, PMID 41781018, PMID 41991689, PMID 42040934
P30CA014520 (3), P01CA042045 (2), P30CA015704 (2), U01CA062491 (2), U10CA180820 (2), 2005 (1), N01CM00070 (1), N01CM27165 (1), P30CA006973 (1), P30CA008748 (1), P30CA015083 (1), P30CA016058 (1), P30CA016059 (1), P30CA022453 (1), P30CA033572 (1)